STAT3 and neoplasm: These experiments indicate that CARD9 signaling in the immune environment of developing colorectal cancers can trigger the tumor-promoting STAT3 pathway within tumor cells, presumably via ILC-mediated IL-22 production, comparable to its role during epithelial regeneration after acute colitis (34, 35).